CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2023—Werfen announced it has completed the acquisition of Immucor after obtaining all necessary regulatory and antitrust approvals. The purchase price was about $2 billion.
“During our more than 50-year history, we have demonstrated our strong commitment to expand our IVD business through organic growth, complemented with highly strategic acquisitions,” Carlos Pascual, Werfen CEO, said in a news release.
Immucor is a privately held corporation with a global presence in transfusion and transplant in vitro diagnostics. Werfen says the acquisition will allow it to expand its portfolio of specialized diagnostics solutions for hospitals and clinical laboratories. The company will have seven technology centers, employ more than 7,000 people worldwide, and have a presence in more than 30 countries.
Werfen, 800-955-9525